How much funding can be received?

Get a non-refundable grant up to $500,000 to cover up to 40% of eligible expenses when your SME partners with a research centre on an artificial intelligence project that accelerates drug discoveries.

grant_single_labels|projects

This grant is available to companies that are conducting R&D or production activities specifically in Quebec. The funding prioritizes collaborative projects within this Canadian province.

Businesses located in Quebec, Canada.

grant_single|admissibleProjectsExample

$220,000

AI algorithm development for neurodegenerative disease drug research

$196,000

Using AI to optimize drug formulation processes for oncology

$220,000

AI-enhanced cardiovascular drug development project

$200,000

Leveraging AI to accelerate antibiotic resistance research

$180,000

Developing AI for drug interaction predictions in a lab setting

$180,000

Creating an AI-driven platform for rare disease drug discovery

grant_single_labels|admissibility

Eligibility for the Partenar-IA grant is determined by specific requirements that firms must meet to qualify.

The project must involve a minimum of two businesses conducting R&D or production activities in Quebec.
At least one of the participating businesses must be a small or medium-sized enterprise (SME) with at least 250 employees.
The project must be carried out in collaboration with one or several research institutions in Quebec, ensuring at least 20% of the project's involvement is with these institutions, such as universities, hospitals, CCTTs, or public research centers.
Each participating business is required to hire at least one intern per year for the duration of the project.
The project must demonstrate a minimal industrial contribution of 25%, which can be in cash and/or in kind.
External funding from non-MEIE sources can cover, at most, 25% of the project's funding arrangement.
The project should have a maximum duration of 2 years.

grant_eligibility_criteria|who_can_apply

This grant supports collaborative R&D projects in biopharmaceuticals using AI by businesses in Quebec.

Collaborative projects between at least two businesses involved in biopharmaceutical R&D in Quebec, with participation from research institutions.
Involvement of at least one SME with a minimum of 250 employees based in Quebec.
Commitment to hire at least one intern per year throughout the project duration.
Requirement for a minimum industrial contribution of 25% towards the project, either in cash or in kind.
Projects receiving funding from other non-MEIE sources, capped at 25% of the total funding arrangement.
Projects should have a maximum duration of 2 years.

grant_eligibility_criteria|who_cannot_apply

Some companies may not be eligible for this grant due to specific exclusion criteria. For example, companies involved in tobacco, alcohol, or adult entertainment industries might not qualify.

Companies engaged in illegal activities.
Non-profit organizations.
Companies not registered or operating in Canada.
Government entities or agencies.

grant_eligibility_criteria|eligible_expenses

Partenar-IA grant is designed to support collaborative R&D projects in the biopharmaceutical sector in Quebec utilizing artificial intelligence. The program aims to foster collaboration between businesses and research institutions to advance technological innovations.

Collaborative R&D projects involving AI applications in biopharmaceutical processes.
Innovative projects enhancing drug discovery and development through machine learning and data analytics.
Integration of AI technologies for improving healthcare outcomes and biomanufacturing efficiency.
Initiatives involving interdisciplinary teams from industries and academic institutions.
Projects contributing to the advancement of personalized medicine through AI-driven insights.

grant_eligibility_criteria|zone

The grant covers specific expenses that are directly related to the collaborative biopharmaceutical R&D project using artificial intelligence.

Personnel salaries and benefits specifically attributed to the project.
Costs associated with the use of equipment and materials essential for the project.
Fees for research institutions' participation and collaboration in the project.
Internship stipends for hiring required interns.
Travel and related expenses directly tied to project execution.
Indirect costs associated with project management and administrative support.

grant_single_labels|criteria

There are evaluation and selection criteria for this grant. The criteria include but are not limited to the applicant's innovation level, impact on the community, and financial viability.

Applicant's innovation level
Impact on the community
Financial viability

grant_single_labels|register

Here are the steps to submit an application for this grant:

Step 1: Preliminary Inquiry and Guidance
- Contact Mathieu Paquette via email at mpaquette@cqdm.org to discuss the project and express your interest in applying.
- Obtain any necessary details or clarifications regarding the application process and eligibility.
Step 2: Gather Required Documentation
- Collect and prepare all necessary documents, including proof of collaborative partnerships with research institutions and evidence supporting eligibility criteria.
- Prepare a detailed project plan highlighting the use of artificial intelligence in biopharmaceutical R&D.
- Compile budget details and outline industrial contributions and other funding arrangements.
Step 3: Complete Application Form
- Access the official application form provided in the Information Guide.
- Accurately complete all sections of the form, ensuring all data is precise and adheres to the specified guidelines.
Step 4: Submit Application
- Review the entire application package to ensure completeness and adherence to requirements.
- Submit the full application package, including the completed form and all supporting documents, before the deadline.
Step 5: Receive Confirmation
- Await a confirmation email acknowledging receipt of the application.
- Ensure to keep a copy of the confirmation for future reference or follow-up.

grant_single_labels|otherInfo

Here are additional relevant details for this grant:

Strong emphasis is placed on cross-sector collaboration between businesses and research institutions.
Successful applicants may receive guidance and support from the grant provider throughout the project duration.
The program aims to strengthen Quebec's position in the biopharmaceutical and AI sectors.
Projects should demonstrate potential for significant advancements or innovations in biopharmaceutical applications.

grant_single_labels|contact

mpaquette@cqdm.org

Apply to this program

Partenar-IA: Catalyzing Collaborative Biopharmaceutical R&D

The Partenar-IA grant supports collaborative biopharmaceutical research and development projects in Quebec with a focus on artificial intelligence. Designed to bolster partnerships between businesses and research institutions, it aims to accelerate innovation and growth in the biopharmaceutical sector.

Detailed Insights into Partenar-IA Grant Opportunities and Benefits

The Partenar-IA grant, orchestrated by CQDM, is a pivotal opportunity for businesses in Quebec to enhance their research and development capabilities, particularly those involving artificial intelligence (AI) within the biopharmaceutical domain. This program not only aims to stimulate technological advancements but also encourages collaborative efforts between various key stakeholders in Quebec's thriving biotech environment.

Focused on facilitating partnerships between at least two businesses including small and medium enterprises (SMEs) and renowned research institutions such as universities, hospitals, and public research centers, the Partenar-IA grant emphasizes the creation of symbiotic relationships that drive innovation. By mandating these collaborations, the program ensures a multidisciplinary approach to tackling current challenges in the pharmaceutical industry, potentially revolutionizing healthcare solutions with AI-driven technologies.

The financial framework of the Partenar-IA grant is structured to provide substantial backing, with up to 50% support on eligible expenses incurred during the project execution. This backing is critical for ensuring that resources are available to leverage cutting-edge AI technologies that can lead to significant advancements in drug discovery, precision medicine, and healthcare delivery systems.

By necessitating the involvement of at least one intern per participating business each year, the grant also supports workforce development, reinforcing the next generation of skilled professionals in Quebec. This investment in human capital is crucial for maintaining a competitive edge in the biopharmaceutical sector, where the integration of AI demands new skill sets and competencies.

Strategically, the grant facilitates projects not exceeding two years in duration with a significant focus on achieving tangible results within a concise timeframe. This focus on swift innovation and implementation ensures that businesses remain at the forefront of global pharmaceutical research trends, quickly adapting to new challenges and opportunities presented by advancements in AI technologies.

The Partenar-IA grant stipulates a minimum industrial contribution of 25%, showcasing a collaborative investment model where private and public funds synergize to maximize impact. This requirement ensures committed engagement from all partners, driving projects towards success and ensuring shared responsibility in achieving the desired outcomes.

Moreover, this program extends a maximum grant of $350,000 per eligible partner business, scaling up to $1,500,000 for larger collaborative ventures involving multiple entities. This scale of funding is instrumental in empowering businesses to undertake ambitious projects that might otherwise be financially prohibitive, thus expanding their research horizon and capabilities.

In a rapidly evolving biopharmaceutical landscape where innovation is paramount, the Partenar-IA grant stands out as a strategic enabler. It allows businesses to not only harness the transformative potential of AI but also to position themselves as leaders in developing next-generation healthcare solutions that can have a profound impact both locally and globally.

Interested businesses are encouraged to contact Mathieu Paquette for more details and to gauge the alignment of their projects with Partenar-IA funding criteria. This proactive engagement from the onset allows for thorough project conceptualization and alignment to ensure a successful application and robust project execution that meets the ambitious goals of this transformative initiative.